Why Investors Are Making A Huge Mistake With Valeant Pharmaceuticals (NYSE:VRX) Stock

- January 11, 2017

takeda_allergan_vrxThe market does not properly appreciate the value of Valeant Pharmaceuticals Intl Inc‘s (NYSE:VRX) two asset sales. With a $5.5 billion market capitalization, the market is telling you that all of Valeant’s business is worth $5.5 billion.

However, Valeant just sold off two small assets than amount to less than 10% of its total revenue for $2.1 billion, almost 40% of VRX stock value. Furthermore, one of those assets, Dendreon, was unlikely a profitable business.

Valeant had bought the Dendreon asset out of bankruptcy a couple years back for a little more than $400 million. Nonetheless, based on the two asset sales, the free market is telling investors that Valeant Pharmaceuticals assets is worth at least $21 billion. In other words, there is a huge disconnect in how the market values VRX stock, and how acquirers and deal makers value Valeant Pharmaceuticals.

Therein lies the reason that VRX stock is such a valuable investment, an illustration that not owning VRX stock is a big mistake.

BNL Members know that we own a small position of VRX stock, but have said that management’s willingness and ability to divest assets would be essential in determining what happens with VRX stock this year. The initial reaction to Valeant’s asset divestment has not been as expected, but that’s ok. Sooner or later, if a company makes good decisions, its stock tends to follow.

What to expect from VRX stock

The rest of this content is exclusive to BNL Members only. (Unlock All Content & Much More)
  • Access all research reports, unlock hidden content, & follow stock coverage on more than 60 companies,
  • Know what stocks are being bought, sold, and held in the market beating BNL Portfolio, David's Dividend Portfolio, and Eddy's Options.
  • Get email notifications and mobile alerts the minute a trade is made. 
  • Join the fastest growing community of investors in the market, and engage with 100s of BNL Members in our Members Only section.

Learn More about BNL Membership and its no risk, no contract, guaranteed results policy!

Get our All Access Package for $85/month!

This entry was posted in Healthcare & Biotech, Members, Mergers & Acquisitions Bookmark the permalink.
RSS feed for this post. Post a comment or leave a trackback: Trackback URL.

Post a Comment

You must be logged in to post a comment.

Join the 100s Who Beat the Market with a BNL Membership

See What Current Members Are Saying

My Complete Access BNL Membership Includes

  • No contract. Guaranteed results. Cancel anytime.
  • Unrivaled Performance. The BNL Portfolio has outperformed the S&P 500 by 150% since October 1, 2015
  • Access. You know what goes in the BNL Portfolio, David’s Dividend Portfolio, and Eddy’s Options.
  • Alerts. You know when a trade is made in all three managed portfolios with application, text, and email alerts
  • Transparency. Verifiable trade records for the BNL Portfolio, David’s Dividends, & Eddy’s Options
  • Research. We have coverage on more than 50 companies
  • Results. Our 10 highest rated stocks outperformed the market by 134% last year
  • Live Chat. Join 100s of other members in an exclusive Members Only section with Chat
  • Growth. We are the fastest growing financial research platform in our industry.
  • Build My Portfolio. You give us your goals, we help you get there
  • Premium Content. Unlock hidden sections in each article. You also get Value of the Month selections and BNL Research Reports.
  • Community. We have professionals and beginners; retirees and college students; the 99% & 1%, but here, we are all equal.

Like what you see? Sign up for our newsletter and get the latest stock picks straight to your email!